Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 8: 1046 - 1050

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.08.008

Clinical research

Application of adjusted global antiphospholipid syndrome score to risk assessment of new thromboembolic events in patients with systemic lupus erythematosus

  • Jia LI ,
  • Ran WANG ,
  • Chun-de BAO ,
  • Nan SHEN ,
  • Qiong FU
Expand
  • Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China
FU Qiong, E-mail: fuqiong5@163.com.

Online published: 2021-08-13

Supported by

National Natural Science Foundation of China(81102267);Youth Medical Talent-Specialist Program

Fold

Abstract

Objective

·To verify the efficacy of adjusted global antiphospholipid syndrome score (aGAPSS) in the risk assessment of new thromboembolic events in the patients with systemic lupus erythematosus (SLE).

Methods

·A total of 330 SLE patients admitted to Renji Hospital, Shanghai Jiao Tong University School of Medicine from December 2012 to March 2016 were retrospectively analyzed. The patients were divided into thrombosis group and control group according to whether there were new thromboembolic events during hospitalization. Demographic data and clinical data of the two groups were collected, and aGAPSS was calculated according to the five risk indicators. Receiver operator characteristic curve (ROC curve) was used to evaluate the diagnostic efficacy of aGAPSS in the patients with new thromboembolic events.

Results

·A total of 60 patients (18.2%) had new thromboembolic events. Compared with the control group, aGAPSS significantly increased in the thrombosis group (P=0.000). The results of ROC curve showed that when the aGAPSS>7 scores, the area under the curve for the diagnosis of new thromboembolic events was 0.752 (95%CI 0.702-0.797), and the sensitivity and specificity were 48.33% and 94.07%, respectively.

Conclusion

·aGAPSS can be used to assess the risk of thromboembolic events in SLE patients and provide reference for clinical treatment decision-making.

Key words： systemic lupus erythematosus (SLE); thromboembolism; adjusted global antiphospholipid syndrome score (aGAPSS)

Cite this article

Jia LI , Ran WANG , Chun-de BAO , Nan SHEN , Qiong FU . Application of adjusted global antiphospholipid syndrome score to risk assessment of new thromboembolic events in patients with systemic lupus erythematosus[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(8) : 1046 -1050 . DOI: 10.3969/j.issn.1674-8115.2021.08.008

References

1 Arkema EV, Svenungsson E, von Euler M, et al. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study[J]. Ann Rheum Dis, 2017, 76(9): 1544-1549.
2 Avi?a-Zubieta JA, Vostretsova K, De Vera MA, et al. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study[J]. Semin Arthritis Rheum, 2015, 45(2): 195-201.
3 Guraieb-Chahín P, Cantú-Brito C, Soto-Mota A, et al. Stroke in systemic lupus erythematosus: epidemiology, mechanism, and long-term outcome[J]. Lupus, 2020, 29(5): 437-445.
4 Sciascia S, Sanna G, Murru V, et al. GAPSS: the global anti-phospholipid syndrome score[J]. Rheumatology (Oxford), 2013, 52(8): 1397-1403.
5 Sciascia S, Radin M, Sanna G, et al. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis[J]. Rheumatology (Oxford), 2018, 57(4): 661-665.
6 Radin M, Sciascia S, Erkan D, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort[J]. Semin Arthritis Rheum, 2019, 49(3): 464-468.
7 Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(8): 2677-2686.
8 D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study[J]. Circulation, 2008, 117(6): 743-753.
9 Garcia L, Velloso MS, Martire MV, et al. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina[J]. Lupus, 2020, 29(14): 1866-1872.
10 Radin M, Schreiber K, Costanzo P, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction[J]. Int J Cardiol, 2017, 240: 72-77.
11 Bahl V, Hu HM, Henke PK, et al. A validation study of a retrospective venous thromboembolism risk scoring method[J]. Ann Surg, 2010, 251(2): 344-350.
12 Hernández-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome[J]. Clin Exp Rheumatol, 2013, 31(3): 382-388.
13 Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events[J]. Arthritis Rheum, 2012, 64(2): 504-512.
14 Chen J, Sun S, Yan Q, et al. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study[J]. Clin Rheumatol, 2016, 35(2): 333-340.
15 Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study[J]. Rheumatology (Oxford), 2015, 54(11): 2071-2075.
16 Sciascia S, Cuadrado MJ, Sanna G, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort[J]. Arthritis Care Res (Hoboken), 2014, 66(12): 1915-1920.
Options
Outlines

/

〈 〉